Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975871 | 0.83 | TLR8 (0.53) | TLR8ALDH1A1MAPT | |
| SCHEMBL28902108 | 0.83 | TLR8 (0.53) | TLR8ALDH1A1MAPT | |
| SCHEMBL10575256 | 0.83 | BCL2 (0.48) | — | |
| SCHEMBL22806612 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL317874 | 0.79 | TLR8 (0.62) | TLR8ALDH1A1KDM4EGAAIKBKB | |
| SCHEMBL13227169 | 0.79 | SMN1; SMN2 (0.55) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL4205004 | 0.79 | ALDH1A1 (0.43) | TLR8ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL3954275 | 0.79 | KMT2A (0.66) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL3209046 | 0.78 | TLR8 (0.53) | TLR8ALDH1A1KDM4EGAAIKBKB | |
| SCHEMBL1019128 | 0.78 | TLR8 (0.70) | TLR8ALDH1A1KDM4EGAAIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | claimed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | claimed |
| CN-119998273-A | Benzyl amino quinoline compound and preparation method thereof | 无锡瓴方生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119998273-A | Benzyl amino quinoline compound and preparation method thereof | 无锡瓴方生物医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024083120-A1 | BENZYLAMINOQUINOLINE COMPOUND AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-106458996-A | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| CN-101157652-B | Antitumor activity bipyridine methyl amine compound and preparation method thereof | UNIV JIANGSU | 2010-08-25 | — | — | CN | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| CN-101157652-A | Antitumor activity bipyridine methyl amine compound and preparation method thereof | UNIV JIANGSU (CN) | 2008-04-09 | — | — | CN | disclosed |
| CN-86100512-A | 2 of antitumor action is arranged, and 4-diamino-6-(N-methyl or formyl radical-replacement benzyl amino) quinoline derivatives is synthetic | — | 1987-09-02 | — | — | CN | disclosed |
| CN-86100512-A | 2 of antitumor action is arranged, and 4-diamino-6-(N-methyl or formyl radical-replacement benzyl amino) quinoline derivatives is synthetic | — | 1987-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TLR8 3013/4885ALDH1A1 1897/4885KDM4E 3028/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | TLR8 3013/4885ALDH1A1 1897/4885KDM4E 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.